Related Experiment Videos
[Piperacillin in in vitro-in vivo combination]
Presse Medicale (Paris, France : 1983)
|December 20, 1986
Summary
Piperacillin, a broad-spectrum antibiotic, is often combined with others to enhance efficacy and prevent resistance, particularly in immunocompromised patients. Combinations with beta-lactams and aminoglycosides show promise, while piperacillin-vancomycin yielded suboptimal results.
Area of Science:
- Pharmacology and Infectious Diseases
- Antimicrobial Resistance
- Clinical Microbiology
Context:
- Piperacillin, a widely used antibiotic, is administered alone or in combination therapies.
- Combined antibiotic therapy is crucial for broadening antibacterial spectrum, achieving synergism, and preventing resistance, especially in immunocompromised patients.
- In vitro studies guide the selection of effective antibiotic combinations.
Purpose:
- To evaluate the efficacy of piperacillin in combination with other antibiotics.
- To explore synergistic and antagonistic effects between different antibiotic classes.
- To assess the potential of novel antimicrobial agents in combating resistant bacterial strains.
Summary:
- Piperacillin is commonly used in combination therapy to combat bacterial infections.
- The most effective combinations involve a beta-lactam antibiotic and an aminoglycoside, supported by in vitro data.
- Piperacillin-vancomycin combination showed less favorable outcomes compared to other regimens.
- Antagonistic effects were observed between certain beta-lactam antibiotics in vitro, with in vivo isolation of mutants.
Impact:
- Highlights the importance of rational antibiotic selection for optimizing treatment outcomes.
- Underscores the challenges posed by antimicrobial resistance in clinical settings.
- Suggests potential for new therapeutic strategies with emerging agents like aztreonam, fluoroquinolones, and beta-lactamase inhibitors.